Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213307098> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W4213307098 endingPage "111" @default.
- W4213307098 startingPage "111" @default.
- W4213307098 abstract "111 Background: Prostate cancer often occurs in an elderly population, at higher risk of drug-drug interactions (DDIs). There is a medical need to increase the knowledge of DDI prevalence and their severity among patients coming from routine care. This study used a prospective approach with the aim to quantify and describe DDIs in medical prescription of prostate cancer treatments. Methods: DDIs were assessed from two perspectives: 1) “real DDI” between the patient’s comedications and the actual anti-cancer agent prescribed; 2) “modelized DDI” between the patient’s comedications and drugs that have proven activity in metastatic endocrine sensitive prostate cancer (MESPC) or castrate resistant prostate cancer (CRPC) settings with positive phase 3 trial and gained EMA approval. French national thesaurus, Micromedex software and complementary manual analysis by pharmacist were used to identified DDIs. Clinical relevance of DDIs was scored using the validated scale of Hatoum. Results: A total of 91 patients were included, 15% of whom were participating in a clinical trial. Some imbalances were observed between patients from clinical trial and routine care (age, ECOG, MESPC/MCRPC). The median number of comedications used per patient was 6 [1-16]. Among real DDI, Enzalutamide was the anticancer agent with the higher risk of interaction (18-54% of patients). In modelized DDI, Enzalutamide and Apalutamide were the two most risky drugs (35-76% and 22-73% depending on Micromedex or Thesaurus analyze). Not all DDIs discovered were clinically significant according to Hatoum scale. Conclusions: DDIs are frequents, according to Micromedex and National Thesaurus tools but pharmacist and physician advices are essentials to determine their potential impacts." @default.
- W4213307098 created "2022-02-24" @default.
- W4213307098 creator A5000284560 @default.
- W4213307098 creator A5003798935 @default.
- W4213307098 creator A5007174985 @default.
- W4213307098 creator A5027731065 @default.
- W4213307098 creator A5033357246 @default.
- W4213307098 creator A5038095307 @default.
- W4213307098 creator A5065018863 @default.
- W4213307098 creator A5067565814 @default.
- W4213307098 creator A5074523547 @default.
- W4213307098 creator A5077441391 @default.
- W4213307098 creator A5079351370 @default.
- W4213307098 creator A5079583275 @default.
- W4213307098 date "2022-02-20" @default.
- W4213307098 modified "2023-10-16" @default.
- W4213307098 title "Evaluation of drug-drug interactions among patients with metastatic prostate cancer in routine care." @default.
- W4213307098 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.111" @default.
- W4213307098 hasPublicationYear "2022" @default.
- W4213307098 type Work @default.
- W4213307098 citedByCount "1" @default.
- W4213307098 countsByYear W42133070982023 @default.
- W4213307098 crossrefType "journal-article" @default.
- W4213307098 hasAuthorship W4213307098A5000284560 @default.
- W4213307098 hasAuthorship W4213307098A5003798935 @default.
- W4213307098 hasAuthorship W4213307098A5007174985 @default.
- W4213307098 hasAuthorship W4213307098A5027731065 @default.
- W4213307098 hasAuthorship W4213307098A5033357246 @default.
- W4213307098 hasAuthorship W4213307098A5038095307 @default.
- W4213307098 hasAuthorship W4213307098A5065018863 @default.
- W4213307098 hasAuthorship W4213307098A5067565814 @default.
- W4213307098 hasAuthorship W4213307098A5074523547 @default.
- W4213307098 hasAuthorship W4213307098A5077441391 @default.
- W4213307098 hasAuthorship W4213307098A5079351370 @default.
- W4213307098 hasAuthorship W4213307098A5079583275 @default.
- W4213307098 hasConcept C121608353 @default.
- W4213307098 hasConcept C126322002 @default.
- W4213307098 hasConcept C143998085 @default.
- W4213307098 hasConcept C2426938 @default.
- W4213307098 hasConcept C2776551883 @default.
- W4213307098 hasConcept C2780035454 @default.
- W4213307098 hasConcept C2780192828 @default.
- W4213307098 hasConcept C2908647359 @default.
- W4213307098 hasConcept C535046627 @default.
- W4213307098 hasConcept C61367390 @default.
- W4213307098 hasConcept C71924100 @default.
- W4213307098 hasConcept C98274493 @default.
- W4213307098 hasConcept C99454951 @default.
- W4213307098 hasConceptScore W4213307098C121608353 @default.
- W4213307098 hasConceptScore W4213307098C126322002 @default.
- W4213307098 hasConceptScore W4213307098C143998085 @default.
- W4213307098 hasConceptScore W4213307098C2426938 @default.
- W4213307098 hasConceptScore W4213307098C2776551883 @default.
- W4213307098 hasConceptScore W4213307098C2780035454 @default.
- W4213307098 hasConceptScore W4213307098C2780192828 @default.
- W4213307098 hasConceptScore W4213307098C2908647359 @default.
- W4213307098 hasConceptScore W4213307098C535046627 @default.
- W4213307098 hasConceptScore W4213307098C61367390 @default.
- W4213307098 hasConceptScore W4213307098C71924100 @default.
- W4213307098 hasConceptScore W4213307098C98274493 @default.
- W4213307098 hasConceptScore W4213307098C99454951 @default.
- W4213307098 hasIssue "6_suppl" @default.
- W4213307098 hasLocation W42133070981 @default.
- W4213307098 hasOpenAccess W4213307098 @default.
- W4213307098 hasPrimaryLocation W42133070981 @default.
- W4213307098 hasRelatedWork W1652439388 @default.
- W4213307098 hasRelatedWork W2096282041 @default.
- W4213307098 hasRelatedWork W2309274182 @default.
- W4213307098 hasRelatedWork W2414042649 @default.
- W4213307098 hasRelatedWork W2590294003 @default.
- W4213307098 hasRelatedWork W2971490708 @default.
- W4213307098 hasRelatedWork W3023947295 @default.
- W4213307098 hasRelatedWork W3132581442 @default.
- W4213307098 hasRelatedWork W3197069188 @default.
- W4213307098 hasRelatedWork W4229076799 @default.
- W4213307098 hasVolume "40" @default.
- W4213307098 isParatext "false" @default.
- W4213307098 isRetracted "false" @default.
- W4213307098 workType "article" @default.